跳至主要内容
临床试验/NCT05297773
NCT05297773已完成不适用

Effects of Resistance vs. Aerobic Training on Ki-67 and Other Health-Related Biomarkers: The NEO-Program, a Randomized Controlled Trial on Breast Cancer Patients Undergoing Neoadjuvant Treatment

Fundacao Champalimaud2 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2022年12月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
132
试验地点
2
主要终点
Changes from baseline Ki67% at the end of the intervention

研究概览

简要总结

A recent consensus study suggested that understanding the impact of exercise on the tumor microenvironment and therapy effectiveness is paramount and should be considered as a research priority. Therefore, the research team intends to address some of the scientific challenges proposed, which represent clear gaps in the current knowledge.

The investigators propose a randomized controlled trial conducted during all neoadjuvant treatment duration that aims to evaluate and compare the effects of two different exercise protocols (aerobic and resistance training) against a relaxation control group on Ki-67% changes as the main outcome in breast cancer patients. Secondary outcomes will be body composition; resting metabolic rate; physical fitness; quality of life, fatigue, depression/anxiety; accelerometry data (physical activity levels, sedentary time); sleep quality; tumor biology (size, hypoxia, and immune profile); glycemic, lipid, and inflammatory profile.

This project will help not only researchers with the design of future exercise intervention protocols but will also help exercise physiologists in the decision-making process when defining training programs. Moreover, the investigators expect that this research program will encourage more cancer patients to exercise. The team expects that patients with breast cancer engaging in structured exercise will show a more marked decrease in Ki-67, tumor size, and hypoxia and increase the tumor-infiltrating lymphocytes (TILs) compared to controls. The investigators anticipate a more noticeable decrease in the preoperative endocrine prognostic index (PEPI) score and in the Residual Breast Cancer (RCB) in both training groups (respectively with hormonal and chemotherapy). Also, frequent declines in physical fitness are expected to be mitigated in exercisers. It is hypothesize that aerobic training will ameliorate cardiorespiratory fitness and fat mass, while the effects of resistance training will be more relevant for muscle strength, muscle mass, and bone health. Both exercise groups will show greater improvements in quality of life, fatigue, depression, anxiety, and sleep quality. Regarding glycemic, lipid, and inflammatory profiles, the investigators expect to see more favorable changes in both training groups, with a more evident decrease in fasting glucose and insulin, HbA1c%, total and LDL-cholesterol, and triglycerides, and the increase in HDL-cholesterol. The increase in C-reactive protein (CRP), tumor necrosis factor -α (TNF-α), interleukin-6 (IL-6), IL-8, IL-1β, IL-1ra, and insulin-like growth factor-1 (IGF-1) and the decrease in brain-derived neutrotophic factor (BDNF), IL-12p70, IL-10, oncostatin M will be smaller in exercise groups.

详细描述

Exercise plays a crucial role in breast cancer prevention and more recently it appears as a safe, non-pharmacological, and cost-effective adjuvant therapy for cancer. Indeed exercise improves the quality of life, fatigue, physical fitness, and also has a positive impact on tumor intrinsic characteristics.

Most of the studies regarding the effects of exercise in breast cancer patients were performed after surgery or in survivors. Despite being a window of opportunity to study the impact of exercise on biological properties of the tumor, namely on proliferation markers, the investigations conducted during the neoadjuvant period are still scarce and most of the literature derives from animal studies. Although originating from pilot investigations, the initial human-based evidence suggests that exercise interventions are feasible during neoadjuvant therapy and can potentially reduce some proliferation markers such as Ki-67 (i.e. a widely used prognostic marker), induce favorable changes in tumor-related genes, and increase survival.

Power and sample calculations (G-Power, Version 3.1.9.2) are based on an effect size of 0.25 for KI-67 while using ANOVA - repeated measures within-between interactions, a power of 0.80, a significance of 0.05, and an expected dropout of 40%. The calculation yielded a total sample size of 120 participants (60 undergoing chemotherapy and 60 undergoing hormone therapy: 20 participants per group per each treatment). The power and sample calculations were performed using a study that reported the effect of medication on KI-67 since no study has evaluated the effects of an exercise intervention on that variable and has obtained significant results.

Participants will be recruited to take part in an intervention study for breast cancer patients undergoing neoadjuvant treatment. The recruitment will take place at Champalimaud Clinical Center Breast Unit / Champalimaud Foundation.

To improve exercise adherence, the following strategies will be implemented:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Histologically breast cancer (stage 0-III); scheduled for neoadjuvant treatment (cohort A - chemotherapy; cohort B - endocrine therapy)
  • •Women aged ≥ 18 years; nonpregnant
  • •Do not be involved in any structured exercise program in the past 6 months
  • •Medical approval to participate in the study
  • •Willingness to attend exercise sessions

排除标准

  • •Treated for any cancer in the past 5 years (except basal cancer)
  • •Uncontrolled heart disease (heart failure, uncontrolled coronary heart disease, and uncontrolled hypertension, cardiac disease)
  • •Diabetes mellitus
  • •Lung condition (chronic obstructive or restrictive pulmonary disease)
  • •Psychological disorders (dementia, Alzheimer, and Parkinson Disease)
  • •Severe disability, or other medical condition that prevents from exercise training
  • •Alcohol or drugs abuse

研究组 & 干预措施

Aerobic Training

Experimental

Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform moderate-to-vigorous intensity cycling exercise.

干预措施: Aerobic Training Group (Behavioral)

Resistance training

Experimental

Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform weight-machine strength exercises of the upper and lower body.

干预措施: Resistance Training Group (Behavioral)

Control Group

Active Comparator

One session per week of relaxation/stretching.

干预措施: Control group (Other)

结局指标

主要结局

Changes from baseline Ki67% at the end of the intervention

时间窗: 4-6 months

Initial tumor biopsy and the post-neoadjuvant surgical specimen will be evaluated. Pathology evaluation will include the Ki67 assessment. The time frame depends on each participant's treatment plan.

次要结局

  • Changes in body mass index (BMI) from baseline to T1 and T2(4-6 months)
  • Changes in hip circumferences from baseline to T1 and T2(4-6 months)
  • Changes in waist circumferences from baseline to T1 and T2(4-6 months)
  • Changes in bone mineral density from baseline to T1 and T2(4-6 months)
  • Changes in lean body mass from baseline to T1 and T2(4-6 months)
  • Changes in phase angle from baseline to T1, T2, T3, T4, T5, T6(4-6 months)
  • Changes in resting metabolic rate from baseline to the end of the intervention(4-6 months)
  • Changes in peak oxygen content from baseline to the end of the intervention(4-6 months)
  • Changes from baseline to T1 and T2 in upper limb strength(4-6 months)
  • Changes from baseline to T1 and T2 in lower limb strength(4-6 months)
  • Change from baseline to T1 and T2 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scale Scores(4-6 months)
  • Change from baseline to T1 and T2 in European Organization for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ BR23) Functional Scale Scores(4-6 months)

研究者

发起方
Fundacao Champalimaud
申办方类型
Other
责任方
Principal Investigator
主要研究者

Maria-Joao Cardoso

Head Breast Surgeon - Medical Doctor

Fundacao Champalimaud

研究点 (2)

Loading locations...

相似试验